AR121193A1 - ANTICUERPOS CONTRA LA INTEGRINA avb8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL - Google Patents
ANTICUERPOS CONTRA LA INTEGRINA avb8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENALInfo
- Publication number
- AR121193A1 AR121193A1 ARP210100199A ARP210100199A AR121193A1 AR 121193 A1 AR121193 A1 AR 121193A1 AR P210100199 A ARP210100199 A AR P210100199A AR P210100199 A ARP210100199 A AR P210100199A AR 121193 A1 AR121193 A1 AR 121193A1
- Authority
- AR
- Argentina
- Prior art keywords
- kidney
- kidney disease
- avb8
- tissue
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Abstract
Se proporcionan métodos y composiciones para tratar una enfermedad renal, tal como enfermedad renal crónica (CKD), en los que los métodos y composiciones comprenden anticuerpos o un fragmento de unión al antígeno de estos que se unen de manera específica y selectiva a la integrina avb8 humana, de la que se descubrió, como se describe, que presenta una expresión muy elevada en células y tejido renales y, en particular, tejido renal enfermo o fibrótico. Los anticuerpos contra la integrina avb8 divulgados se unen a la integrina avb8 humana en el riñón y bloquean la activación de TGF-b a partir de su forma latente en el tejido renal. Los anticuerpos contra avb8 en los métodos divulgados reducen, atenúan o anulan la fibrosis renal, que está asociada con la actividad de la integrina avb8 y TGF-b en el tejido renal. Los anticuerpos y métodos divulgados tratan de manera eficaz la enfermedad renal, en particular, la fibrosis asociada con la enfermedad renal, tal como CKD, en individuos que lo necesite.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966258P | 2020-01-27 | 2020-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121193A1 true AR121193A1 (es) | 2022-04-27 |
Family
ID=74561850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100199A AR121193A1 (es) | 2020-01-27 | 2021-01-27 | ANTICUERPOS CONTRA LA INTEGRINA avb8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230112035A1 (es) |
EP (1) | EP4096785A1 (es) |
JP (1) | JP2023511686A (es) |
KR (1) | KR20220132567A (es) |
CN (1) | CN115151305A (es) |
AR (1) | AR121193A1 (es) |
AU (1) | AU2021213403A1 (es) |
BR (1) | BR112022014633A2 (es) |
CA (1) | CA3167390A1 (es) |
CL (1) | CL2022001999A1 (es) |
CO (1) | CO2022011661A2 (es) |
CR (1) | CR20220392A (es) |
EC (1) | ECSP22066085A (es) |
IL (1) | IL294814A (es) |
MX (1) | MX2022009165A (es) |
TW (1) | TW202140554A (es) |
WO (1) | WO2021151889A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
SG183356A1 (en) * | 2010-02-18 | 2012-09-27 | Univ California | INTEGRIN aVß8 NEUTRALIZING ANTIBODY |
SG2014014237A (en) | 2011-08-17 | 2014-07-30 | Univ California | Antibodies that bind integrin alpha-v beta-8 |
ME03678B (me) | 2014-06-17 | 2020-10-20 | Univ California | Unapređena alfa-v beta-8 antitela |
JP2020523319A (ja) * | 2017-06-07 | 2020-08-06 | シルバーバック セラピューティックス インコーポレイテッド | 免疫調節化合物の抗体コンジュゲートおよびその使用 |
-
2021
- 2021-01-13 TW TW110101209A patent/TW202140554A/zh unknown
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Search and Examination
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en active Application Filing
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 JP JP2022545136A patent/JP2023511686A/ja active Pending
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 AU AU2021213403A patent/AU2021213403A1/en active Pending
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230112035A1 (en) | 2023-04-13 |
MX2022009165A (es) | 2022-08-16 |
EP4096785A1 (en) | 2022-12-07 |
CN115151305A (zh) | 2022-10-04 |
TW202140554A (zh) | 2021-11-01 |
KR20220132567A (ko) | 2022-09-30 |
BR112022014633A2 (pt) | 2022-09-13 |
ECSP22066085A (es) | 2022-09-30 |
CR20220392A (es) | 2022-09-07 |
CL2022001999A1 (es) | 2023-01-27 |
AU2021213403A1 (en) | 2022-09-15 |
JP2023511686A (ja) | 2023-03-22 |
IL294814A (en) | 2022-09-01 |
WO2021151889A1 (en) | 2021-08-05 |
CA3167390A1 (en) | 2021-08-05 |
CO2022011661A2 (es) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121193A1 (es) | ANTICUERPOS CONTRA LA INTEGRINA avb8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL | |
PE20081635A1 (es) | Agentes para suprimir la reaccion de rechazo cronica | |
EA200901211A1 (ru) | Антигены белка с5 и их применение | |
EA201891009A1 (ru) | Соединения пиримидиндиона | |
EA201691877A1 (ru) | Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома | |
AR079944A1 (es) | Anticuerpo neutralizante de la actividad de un anticoagulante | |
DOP2011000002A (es) | Agentes de fijación al receptor notch1 y metodos de uso de los mismos | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
PE20211786A1 (es) | Anticuerpos humanizados contra c-kit | |
EA201300988A1 (ru) | Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол | |
UY37967A (es) | Compuestos y métodos para la reducción de la expresión de snca | |
UY38926A (es) | INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA | |
BR112022004861A2 (pt) | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro | |
CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
EA202190094A1 (ru) | Антитела против cd40 для применения в лечении аутоиммунного заболевания | |
EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
EA201990613A1 (ru) | Антитела против гремлина-1 (grem1) и способы их применения для лечения легочной артериальной гипертензии | |
TR201901268T4 (tr) | Mezenkimal kök hücreleri ve bunların kullanımları. | |
EA201000991A1 (ru) | Наркотические эмульсионные композиции для лечения боли после хирургического вмешательства | |
EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
EA202190590A1 (ru) | Соединения и способы лечения грибковых инфекций | |
EA202190504A1 (ru) | Способы лечения псориаза | |
CL2022002078A1 (es) | Anticuerpos contra klk5 | |
BR112022006184A2 (pt) | Tratamento baseado em biomarcadores da glomeruloesclerose segmentar focal e doença renal diabética | |
EA202192751A1 (ru) | Композиции и способы для лечения потери слуха |